Coronary Syndrome
📧 Sign up to get email alerts when something new happens for Coronary Syndrome.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-09-16FDA Approved: CLOPIDOGREL BISULFATE — Supplemental Application (Dr.Reddy's Laboratories Inc)
FDA approves a supplemental application for clopidogrel bisulfate from Dr. Reddy's Laboratories Inc, pertaining to the approved generic prod…
-
CLINICAL_TRIALS trial_result · 2022-09-16Clinical Trial Update: Allopurinol in Acute Coronary Syndrome [Phase 4]
A Phase 4 trial update evaluating allopurinol in patients with acute coronary syndrome has completed.
-
FDA approval · 2022-09-12FDA Approved: CLOPIDOGREL BISULFATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved Sun Pharmaceutical Industries’ supplemental application for clopidogrel bisulfate, indicating regulatory approval of change…
-
CLINICAL_TRIALS trial_result · 2022-09-07Clinical Trial Update: Effect of Pentoxifylline on Endothelial Dysfunction in Patients With Acute Coronary Syndrome [Phase 2, Phase 3]
A clinical trial update evaluating pentoxifylline for endothelial dysfunction in patients with acute coronary syndrome across Phase 2 and Ph…
-
CLINICAL_TRIALS trial_result · 2022-08-31Clinical Trial Update: Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes [Phase 3]
Phase 3 clinical trial investigating influenza vaccination to prevent cardiovascular events after acute coronary syndromes has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-07-26Clinical Trial Update: Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence [Phase 3]
A Phase 3 clinical trial update evaluating generics of P2Y12 platelet inhibitors beyond bioequivalence for cardiovascular diseases including…
-
CLINICAL_TRIALS trial_result · 2022-07-07Clinical Trial Update: Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS [Phase 3]
A Phase 3 trial comparing ticagrelor 60 mg versus ticagrelor 90 mg in elderly patients with acute coronary syndrome has completed recruitmen…
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients (AGREEMENT) [Phase 4]
Phase 4 clinical trial update evaluating glycemic range during acute coronary syndrome in non-diabetic patients has completed.
-
FDA approval · 2022-03-31FDA Approved: CLOPIDOGREL BISULFATE — Supplemental Application (RADHA PHARMACEUTICALS, INC.)
FDA approved a supplemental application for clopidogrel bisulfate (Radha Pharmaceuticals, Inc.) under an ANDA, confirming its status as a ge…
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome [Phase 3]
Phase 3 clinical trial update for MetCool ACS evaluating Metformin 'cooling' effect in metformin-naive patients treated with PCI for Acute C…
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: Effects of Beta-blockade on Platelet Aggregation in Acute Coronary Syndrome [Phase 4]
Phase 4 trial update examining the effects of beta-blockade on platelet aggregation in patients with acute coronary syndrome.
-
CLINICAL_TRIALS trial_result · 2022-03-28Clinical Trial Update: Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome [Phase 4]
Phase 4 trial update assessing low-dose PCSK9 inhibitor with statins and its effect on serum lipids in Chinese patients with acute coronary …
-
CLINICAL_TRIALS trial_result · 2022-03-17Clinical Trial Update: Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome [Phase 4]
Phase 4 trial investigating switching from ticagrelor to prasugrel in patients with acute coronary syndrome.
-
CLINICAL_TRIALS trial_result · 2022-03-10Clinical Trial Update: Healthy Heart Habits [Phase 1, Phase 2]
Clinical trial update for Healthy Heart Habits reporting Phase 1 and Phase 2 results; completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-03-03Clinical Trial Update: Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study [Phase 4]
A Phase 4 clinical trial update evaluating a cholesterol-lowering regimen combining bempedoic acid and ezetimibe (an ACL-inhibiting approach…
-
CLINICAL_TRIALS trial_result · 2022-02-22Clinical Trial Update: Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome [Phase 4]
A Phase 4 trial comparing low molecular weight heparin (LMWH) to rivaroxaban in Chinese patients hospitalized with acute coronary syndrome e…
-
FDA approval · 2022-02-15FDA Approved: HEPARIN SODIUM — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for Heparin Sodium submitted by Sandoz Inc., indicating an additional regulatory action on this gene…
-
FDA approval · 2022-02-14FDA Approved: PRASUGREL — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for prasugrel from Aurobindo Pharma Limited, enabling a generic version of the antiplatelet drug…
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia [Phase 2]
Phase 2 trial update on antithrombotic therapy for Acute Coronary Syndrome and Coronary Artery Ectasia; status is unknown.
-
CLINICAL_TRIALS trial_result · 2022-02-09Clinical Trial Update: Influenza Vaccination During Coronavirus Disease 2019 Outbreak After Acute Coronary Syndrome and Chronic Heart Failure [Phase 4]
Phase 4 clinical trial update evaluating influenza vaccination in patients with acute coronary syndrome and chronic heart failure during the…
-
FDA approval · 2022-02-04FDA Approved: PRASUGREL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application from Amneal Pharmaceuticals LLC for a generic prasugrel product.
-
FDA approval · 2022-01-12FDA Approved: HEPARIN SODIUM — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for HEPARIN SODIUM from Sagent Pharmaceuticals, authorizing changes under an approved supplemental f…
-
FDA approval · 2022-01-12FDA Approved: HEPARIN SODIUM — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for Heparin Sodium from Sagent Pharmaceuticals, confirming regulatory status and updates related to …
-
CLINICAL_TRIALS trial_result · 2021-12-03Clinical Trial Update: Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI [Phase 4]
Phase 4 trial update evaluating cangrelor in comatose OHCA survivors undergoing primary PCI has completed.
-
CLINICAL_TRIALS trial_result · 2021-11-12Clinical Trial Update: Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI) [Phase 4]
Phase 4 clinical trial evaluating prasugrel switching in ACS patients who underwent PCI; study completed with posted results in 2021.